Proteomics nails near perfect results for endometriosis blood test

The tests also showed an excellent diagnostic performance, with an 0.852 accuracy rating for identifying early-stage disease when measured against healthy patients.

For comparison, the statistical performance of the gold-standard diagnostic test for prostate cancer in men – the prostate-specific antigen (PSA) diagnostic test which measures the PSA protein in blood – has a 0.68 accuracy rating.

Proteomics International managing director Dr Richard Lipscombe said: “The integration of the PromarkerEndo blood test into clinical practice could streamline diagnosis, improve patient outcomes and deepen the understanding of endometriosis. This advancement marks a significant step toward non-invasive, personalised care for a condition that has long been underserved by current medical approaches.”

The company says the new findings, published in the well-regarded medical journal Human Reproduction, have built on its discoveries earlier in the year that showed off PromarkerEndo’s ability to successfully pick up late-stage endometriosis in patients.

Proteomics is aiming for a clinical launch of its diagnostic tool in Australia between March and June next year then plans to expand globally. It is also refining the test’s diagnostic algorithm and developing a cloud-based software hub for efficient results reporting.

The company is also progressing an option to deliver the tests directly to the consumer/patient by leveraging the framework for its predictive test for diabetic kidney disease and diagnostic test for oesophageal cancer, which it plans to launch in the first three months of 2025.

Endometriosis costs Australia $9.7 billion annually in healthcare and lost productivity. With its focus on early intervention and personalised care, PromarkerEndo appears to offer a beacon of hope for those living with the condition.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au